1. Programmed Cell Death and Functional Activity of Platelets in Case of Oncohematologic Diseases.
- Author
-
Martyanov AA, Ignatova AA, Svidelskaya GS, Ponomarenko EA, Gambaryan SP, Sveshnikova AN, and Panteleev MA
- Subjects
- Adolescent, Biphenyl Compounds pharmacology, Blood Coagulation drug effects, Calcium metabolism, Child, Child, Preschool, Female, Humans, Male, Nitrophenols pharmacology, Phosphatidylserines blood, Piperazines pharmacology, Sulfonamides pharmacology, Antineoplastic Agents pharmacology, Apoptosis drug effects, Blood Platelets drug effects, Hematologic Neoplasms blood, Hematologic Neoplasms drug therapy
- Abstract
Programmed cell death of non-nucleated blood cells - platelets - could be associated with pathophysiology of oncologic and oncohematologic diseases. It contributes to both bleedings (caused by the thrombocytopenia, which is induced by elimination of the platelets) and thrombosis (caused by the processes of blood coagulation on the surface of phosphatidylserine exposing platelets). Here we characterized functional responses of platelets from the patients with various oncological disorders undergoing chemotherapy and compared them to the platelets from the healthy donors and platelets pre-incubated with apoptosis inducer ABT-737. Some patients exhibited diminished capability of platelets to aggregate. Immunophenotyping of these platelets revealed their pre-activation in comparison to the platelets from the healthy donors. Calcium signaling analysis revealed that in the patient-derived platelets, as well as in the apoptotic platelets, intracellular calcium levels were increased in resting cells. However, moderate level of this increase together with weak expression of phosphatidylserine allows us to assume that apoptotic processes in the circulating platelets from the patients are limited.
- Published
- 2020
- Full Text
- View/download PDF